Sticking out from the Wall Street crowd is no easy feat at the best of times. Now imagine the plight of money managers across the ever-competitive investment industry, who are struggling to assert ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.